No Data
No Data
Atossa Therapeutics Completes Enrollment for 80-Milligram Cohort in Study of Potential Breast Cancer Treatment
Express News | Atossa Therapeutics Completes Enrollment Of 80mg Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen For ER+ / HER2- Breast Cancer
Express News | Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-in Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for Er+ / Her2- Breast Cancer
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
tian liang : These few days
DJqualls : why?
5060 OP DJqualls : do your own work!!!